Genetically raised levels of C-reactive protein (CRP, an inflammatory protein) are associated with protection against schizophrenia, according to a Mendelian randomization study published this week in PLOS Medicine. The study, published by Behrooz Z. Alizadeh of the University Medical Centre Groningen, The Netherlands, and colleagues, found a lack of association between CRP and a number of somatic and psychiatric disorders, suggesting that many disease-associated rises in CRP levels might be a response rather than cause of the disease.
Observational studies have shown that increased blood levels of CRP are associated with certain diseases, suggesting these diseases might be controlled with drugs that reduce CRP levels. Alizadeh and colleagues undertook a Mendelian randomization study, using genetic variants that affect CRP levels to determine if elevated CRP has a genetically predictable, causal relationship with 32 common complex disorders. The researchers report that genetically increased CRP was significantly associated with a reduced risk of schizophrenia (for 10% increased CRP, odds ratio [OR] 0.86 [95% CI 0.79-0.94]; p < 0.001). In addition, they found nominally significant associations (which remain to be confirmed) between genetically increased CRP levels and increased risk of arthritis, elevated serum albumin, raised blood pressure, and bipolar disorder. There was no evidence for an effect of genetically increased CRP levels on any of the other 27 outcomes studied.
Though this is one the largest studies on the topic, the reliability of these findings depends on the validity of the assumptions of Mendelian randomization, including the ability of the genetic scores to explain variations in CRP level. However, these findings suggest that interventions designed to lower CRP level are unlikely to decrease the risk of people developing the majority of common complex somatic and neuropsychiatric outcomes.
Materials provided by PLOS. Note: Content may be edited for style and length.
Cite This Page: